South & Central America Antibody Drug Conjugates Market

The South & Central America antibody drug conjugates market was valued at US$ 264.91 million in 2022 and is expected to reach US$ 799.23 million by 2030; it is estimated to grow at a CAGR of 14.8% from 2022 to 2030.

Escalating Pipeline of ADCs Fuels the South & Central America Antibody Drug Conjugates Market

Various biopharmaceutical companies are developing ADCs owing to the rising interest in ADCs as promising cancer treatment. Companies such as ImmunoGen, Inc; NBE-Therapeutics, Seagen Inc; ADC Therapeutics; Merck KGaA; Sorrento Therapeutics, Inc; Mythic Therapeutics; Sutro Biopharma; Peak Bio; Regeneron Pharmaceuticals; Asana BioSciences; Sanofi; Navrogen, Inc; and OBI Pharma have ADCs in the different developmental phases. It is anticipated that the commercial launch of the ADCs developed will significantly enhance market size.

The companies have developed a broad list of promising ADCs in the different clinical stages and pipelines to be commercialized. The list of ADCs in the pipeline includes Camidanlumab tesirine, ADCT-602, Zynlonta, ADCT-901, ADCT-701, ADCT-212, ADCT-601, Ladiratuzumab Vedotin, NBE-002, IMGN151, IMGN-632, IMGC 936, IMGN-151, OBI 999, R 992, NAV-001, MYTX-011, M1231, STI-6129, Torpedo, BCMA ADC, REGN5093-M114, ASN004, TR 1801 ADC.

Companies have also shared pre-clinical data related to their respective products. For instance, in April 2023, Mythic Therapeutics announced preclinical data for its MYTX-011 (cMET-targeting ADC). The data published included the highlights of MYTX-011 intended to treat a broad range of cMET+ cancers. Likewise, at the Association for Cancer Research Annual Meeting in April 2023, Araris Biotech AG announced its preclinical data on anti-Nectin-4 and anti-HER2 ADCs. The two ADCs were developed using the company's proprietary linker technology. The data demonstrated improved anti-tumor activity of anti-Nectin-4 and anti-HER2 ADCs compared to respective FDA-approved ADCs in head-to-head in-vivo studies. Thus, the rise in innovative ADCs will likely propel the market growth exponentially in the coming years.

South & Central America Antibody Drug Conjugates Market Overview

The antibody drug conjugates market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The market growth in this region is primarily attributed increasing awareness regarding cancer screening. For instance, the Brazilian Association of Intestinal Cancer Prevention (ABRAPRECI) and the Colorectal Cancer Prevention and Screening Program have been initiated to create awareness among the masses. The growth in awareness campaigns and screening programs has increased the demand for colonoscopy services. In addition, in December 2020, a French diagnostic firm, HalioDx signed an agreement with Diagnosticos da America (DASA) to distribute its Immunoscore colon cancer risk-assessment test in Brazil. Immunoscore assists in predicting the risk of relapse in early-stage colon cancer by measuring host immune responses at tumor sites, which helps plan treatment strategies. Under the agreement terms, in Brazil, Sao Paulo-based DASA has exclusive distribution rights to the test, offering it through 40 laboratory networks. As ADCs target specific cancer cells and release toxic drug into the cancer cells, the rising cases of cancer in the country are expected to boost the market in the future. Also, the current plans for colorectal cancer screening in Argentina, the incidence of colorectal cancer is expected to increase shortly due to the discovery of previously undiagnosed diseases. Therefore, these factors are likely to contribute to the progress of the antibody drug conjugates market in Argentina during the forecast period.

South & Central America Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Antibody Drug Conjugates Strategic Insights

Strategic insights for the South & Central America Antibody Drug Conjugates provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

South & Central America Antibody Drug Conjugates Report Scope

South & Central America Antibody Drug Conjugates Regional Insights

The geographic scope of the South & Central America Antibody Drug Conjugates refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

South & Central America Antibody Drug Conjugates Market Segmentation

The South & Central America antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.

Based on technology, the South & Central America antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.

Based on application, the South & Central America antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.

Based on distribution channel, the South & Central America antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.

Based on country, the South & Central America antibody drug conjugates market is categorized into Brazil, Argentina, the Rest of South & Central America. Brazil dominated the South & Central America antibody drug conjugates market in 2022.

Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the South & Central America antibody drug conjugates market.